A dual-action option for metabolic and hormonal support in PCOS.
Metformin ER (extended release) is a first-line treatment for insulin resistance in PCOS. By supporting how your body responds to insulin, it may help lower androgen levels — which are associated with symptoms like irregular periods, excess hair growth, weight gain, and acne.*
A comprehensive approach to PCOS and insulin resistance. Metformin supports insulin sensitivity, while tirzepatide acts on GLP-1/GIP receptors to support appetite regulation, fat metabolism, and hormonal balance.*
The proven foundation of PCOS treatment. Addresses insulin resistance through a single metabolic pathway.
PCOS-related insulin resistance is a complex metabolic condition that doesn't respond to a single switch. Metformin ER tackles insulin resistance at the cellular level — improving how your liver and muscles process glucose. But it leaves appetite signaling and fat metabolism largely untouched.
Tirzepatide fills the gap. As a dual GLP-1/GIP receptor agonist, it targets the hormonal pathways that control hunger, satiety, and how your body stores fat. Together, they create a comprehensive metabolic reset that neither medication can achieve alone — addressing insulin, appetite, weight, and androgen levels simultaneously.
Get the Complete Plan — $221/mo →Two medications, three metabolic pathways, one comprehensive approach to PCOS and weight management.
Activates AMPK in your liver and muscles, helping cells absorb glucose efficiently and reducing the excess insulin production that drives PCOS symptoms like acne, hirsutism, and irregular cycles.
Activates GLP-1 receptors to slow gastric emptying and signal satiety to the brain. This directly reduces the intense hunger and carb cravings that make PCOS weight management so frustrating.
The GIP receptor activation is what sets tirzepatide apart. It enhances your body's ability to metabolize stored fat — particularly visceral fat around the abdomen, which is closely linked to insulin resistance.
Together, falling insulin levels reduce ovarian androgen production while improved fat metabolism lowers estrogen imbalance. The result is a cascade of improvements across periods, skin, hair, mood, and energy.
Up to 70% of women with PCOS have insulin resistance — even at a normal weight. When cells don't respond to insulin, the body overproduces it. Excess insulin triggers androgen overproduction and signals the body to store fat, especially around the abdomen. This creates a self-reinforcing cycle that a single-pathway treatment can only partially break.
Metformin ER breaks the cycle at the insulin level. Tirzepatide breaks it at the appetite and fat storage level. Together, they interrupt the loop from multiple points simultaneously.
Both medications are backed by extensive clinical data — and the combination shows stronger outcomes than either alone.
Start Metformin ER at 500mg daily with your evening meal. Begin tirzepatide at the lowest dose via weekly subcutaneous injection. Your body adjusts to both medications during this period.
Most patients notice reduced appetite and fewer cravings as tirzepatide takes effect. Metformin begins improving fasting glucose levels. Your provider may gradually increase the metformin dose during this period.
Weight loss becomes measurable. Energy improves. Menstrual cycles may begin to regulate. The dual-pathway effect compounds as both medications reach steady-state levels in your system.
Significant improvements across weight, hormonal balance, skin clarity, and cycle regularity. Androgen levels drop as insulin resistance improves. Many patients report feeling like a different person by this stage.
These typically resolve within the first 2-4 weeks as your body adjusts. The ER formulation significantly reduces these compared to standard metformin.
Your provider will monitor bloodwork periodically. B12 supplementation may be recommended for long-term users.
These tend to lessen as your body adjusts over the first 2-4 weeks.
Not recommended during pregnancy. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not use tirzepatide. Tell your provider about all medications you take. If prescribed.
Both plans include free shipping, a one-time $20 doctor visit, and ongoing physician support. Cancel anytime. If prescribed.
Metformin improves how your cells respond to insulin — it's effective, but it works through a single pathway. Tirzepatide activates two additional pathways (GLP-1 and GIP receptors) that control appetite, satiety, and fat metabolism. The combination addresses PCOS from three angles simultaneously: insulin sensitivity, appetite regulation, and fat storage. This is why clinical outcomes are significantly stronger with the dual approach.
Most patients notice appetite and craving changes within 2-4 weeks as tirzepatide takes effect. Measurable weight loss typically begins within the first month. Menstrual regularity, skin improvements, and hormonal balance follow over 2-6 months as insulin and androgen levels normalize from the combined effect.
Yes — metformin and tirzepatide work through completely different mechanisms and are commonly prescribed together. They don't compete or interfere with each other. Your Oana physician will review your full health history during the intake to confirm the combination is appropriate for you. If prescribed.
It's straightforward. Metformin ER is a daily oral tablet taken with your evening meal. Tirzepatide is a once-weekly subcutaneous injection (similar to an insulin pen — a small, virtually painless self-injection). So it's one pill daily + one injection weekly.
'Okay' results are common with metformin-only treatment — it addresses insulin resistance but doesn't tackle appetite, fat metabolism, or cravings. Many women find they plateau with metformin alone, especially with weight. Adding tirzepatide often breaks through that plateau because it targets the metabolic pathways metformin can't reach.
It depends on your goals. If metformin alone is managing your symptoms well, it may be all you need. But if you're dealing with stubborn weight, intense cravings, or symptoms that haven't fully responded to metformin, tirzepatide typically produces substantially stronger improvements. Many women find the results justify the investment — especially compared to spending $200-600/month on diet programs, supplements, and gym memberships that don't address the hormonal root cause.
Absolutely. Many women start with metformin at $22/month and add tirzepatide when they're ready for more aggressive results. Your Oana physician can adjust your plan at any time — no new health intake required.
The most common side effects are mild GI symptoms (nausea, bloating) from metformin and decreased appetite from tirzepatide. Both typically resolve within 2-4 weeks. The extended-release metformin formulation reduces GI issues significantly. Many patients report that the appetite reduction from tirzepatide is actually a welcome effect, not a side effect.
It depends on your situation. Some patients use the combination for 6-12 months to achieve metabolic reset and significant weight loss, then taper tirzepatide while continuing metformin. Others maintain both long-term. Your provider will work with you to find the right approach based on your goals and progress.
Metformin ER (extended release) releases the medication slowly over 8-12 hours, while standard metformin releases it all at once. The ER version causes significantly fewer stomach-related side effects, which is especially important when taking it alongside tirzepatide.
Complete a 5-minute online health intake. A licensed provider will review your information within 1-2 business days.
Free shipping · Cancel anytime · No hidden fees · If prescribedNotes & citations
1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (2022).
2. Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis (2025). Evidence for combination metabolic benefit is inferred from incretin-based combination studies in PCOS rather than Oana's compounded tirzepatide specifically.
Important: Metformin is FDA-approved for type 2 diabetes and may be prescribed off-label for PCOS. Tirzepatide dispensed through Oana is a compounded preparation prepared by a licensed compounding pharmacy. Compounded drugs are not FDA-approved and are not evaluated by the FDA for safety or efficacy. A licensed clinician will review your health intake to determine whether treatment is appropriate. Individual results vary. Oana is not affiliated with Eli Lilly. Do not use tirzepatide if you are pregnant or if you have a personal or family history of medullary thyroid carcinoma or MEN 2. If prescribed.